Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Acute lymphoblastic leukemia (ALL) Clinical Trials

Protocol Number Title
2005LS036
MT2005-02 Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Non-Myeloablative Preparative Regimen
2005LS043
MT2005-10 Transplantation of Unrelated Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloblative Preparative Regimen
2005LS075
MT2005-25 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
2007NT102
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Samples.
2009NTLS130
Hematologic Malignancy Tissue Bank Formerly: "Leukemia, Lymphoma and MDS Tissue Bank" Formerly: "Leukemia and MDS Tissue Bank" & "Pediatric Leukemia Tissue Bank"
2010NTCG113
COG AALL08B1 - Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
2011CG161
COG AALL1131 - A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations. Additional Title: Per Case Reimbursement NIH National Clinical Trials Network (NCTN) BIQSFP Grant U10CA180886-02S7 Add: AALL1131 Osteonecrosis Sub-study Per Case Reimbursement
2012CG099
COG ACCL1033 - A Comprehensive Approach to Improving Medication Compliance in Pediatric ALL
2014CG089
COG AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
2014CG123
MT2016-21 : COG AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) "AALL1331 - Amgen, Inc."
2014LS093
HM2014-26 DT2219 immunotoxin for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia or lymphoma
2014UC022
HM2015-04 : Novartis CCTL019B2205J; HM2015-04: A Phase II, Single Arm, Multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-Cell Acute Lymphoblastic Leukemia
2015CG031
ACCL1333/CV185-155 - A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy

14 trials displayed